Compass CEO Kabir Nath quit high-paying job to work on psychedelic pill for treating depression

Kabir Nath left pharma to lead Compass Pathways’ development of COMP360, a synthetic psilocybin treatment for treatment-resistant depression.
Read the full story on Hindustan Times Opens hindustantimes.com in a new tab
This is a short summary of a story published by Hindustan Times, shown with a link to the original. The full story, photo and reporting belong to Hindustan Times.








